

WHAT IS CLAIMED:

1. A composition comprising:
 - (a) microspheres or microparticles of at least one polymer of non-animal origin selected from the group consisting of lactic acid polymers, glycolic acid polymers, and lactic acid-glycolic acid co-polymers;
 - (b) a hydrogel comprising water and a cellulose-derivative gelling agent; and
 - (c) polysorbate 80 in an amount between 0.05% to 1% by weight.
2. The composition of claim 1, wherein the at least one polymer is a lactic acid selected from poly-L-lactic acid, poly-D-lactic acid, and mixtures thereof.
3. The composition of claim 2, wherein the at least one polymer is poly-L-lactic acid.
4. The composition of claim 1, wherein the at least one polymer occurs in an amount between 5 mg/mL and 50 mg/mL.
5. The composition of claim 1, wherein the cellulose-derivative gelling agent is carboxymethylcellulose or hydroxypropylmethylcellulose.
6. The composition of claim 5, wherein the cellulose-derivative gelling agent is carboxymethylcellulose.
7. The composition of claim 6, wherein the carboxymethylcellulose is sodium carboxymethylcellulose.
8. The composition of claim 6, wherein cellulose-derivative gelling agent occurs in an amount between 0.5% to 4% by weight.
9. The composition of claim 8, wherein the cellulose-derivative gelling agent occurs in an amount of 2% by weight.

10. The composition of claim 1, wherein the polysorbate 80 occurs in an amount of 0.05% by weight.
11. The composition of claim 1, wherein the composition exhibits a viscosity less than 100 mPas.
12. The composition of claim 11, wherein the composition exhibits a viscosity less than 60 mPas.
13. The composition of claim 1, wherein the composition exhibits a viscosity between 5 to 45 mPas.
14. The composition of claim 1, wherein the ratio between the cellulose-derivative gelling agent and the polysorbate 80 is between 100:1 to 1:1.
15. The composition of claim 14, wherein the ration between the cellulose-derivative gelling agent and the polysorbate 80 is between 50:1 and 10:1.
16. The composition of claim 1, wherein the microspheres or microparticles are bioresorbable.
17. The composition of claim 16, wherein the microspheres or microparticles are bioresorbable within a period of about 1 year to about 3 years.
18. The composition of claim 1, wherein the composition comprises microspheres or microparticles at a concentration between 5 to 20 mg/mL.
19. The composition of claim 18, wherein the composition comprises microspheres or microparticles at a concentration between 17 to 18 mg/mL.

20. The composition of claim 1, wherein the microspheres or microparticles are between about 20 to 100 μm in size.
21. The composition of claim 20, wherein the microspheres or microparticles exhibit a median size of about 40 μm in size.
22. The composition of claim 1, wherein the microspheres or microparticles exhibit a molecular weight of between 50 to 500 kDa.
23. The composition of claim 22, wherein the microspheres or microparticles exhibit a molecular weight of between 50 to 200 kDa.
24. The composition of any one of claims 1-23, wherein the composition further comprises a local anesthetic.
25. The composition of claim 24, wherein the local anesthetic is a amide-type or ester-type local anesthetic.
26. The composition of claim 24 or 25, wherein the local anesthetic is selected from the group consisting of: bupivacaine, butanilicaine, carticaine, cinchocaine (dibucaine), clibucaine, ethyl parapiperidinoacetylaminobenzoate, etidocaine, lignocaine (lidocaine), mepivacaine, oxethazaine, prilocaine, ropivacaine, tolycaine, trimecaine, vadocaine, articaïne, levobupivacaine, amylocaine, cocaine, propanocaine, clormecaine, cyclomethycaine, proxymetacaine, amethocaine (tetracaine), benzocaine, butacaine, butoxycaine, butyl aminobenzoate, chloroprocaine, dimethocaine (larocaine), oxybuprocaine, piperocaine, parethoxycaine, procaine (novocaine), propoxycaine, and tricaine; or a combination thereof.
27. The composition of any one of claims 1-26, wherein the composition is aseptic.
28. The composition of claim 27, wherein asepsis is achieved by irradiation or heat sterilization.

29. The composition of any one of claims 1-28, wherein the composition further comprises sodium chloride, a phosphate buffer, and a pharmaceutically acceptable carrier.
30. The composition of any one of claims 1-29, wherein the composition exhibits a sodium chloride concentration of 0.9% w/v.
31. The composition of any one of claims 1-30, wherein the composition is injectable.
32. The composition of claim 31, wherein the injectable composition is an injectable implant.
33. A pre-filled syringe or vial comprising the composition of any one of claims 1-32.
34. An injectable implant comprising the composition of any one of claims 1-32.
35. The injectable implant of claim 34, wherein the injectable implant is for intradermal or subcutaneous injection into a body of a subject in need thereof.
36. A method of performing reparative or esthetic dermatologic treatment, the method comprising injecting a subject with a composition of any one of claims 1-32.
37. The method of claim 36, wherein the injection is intradermal, subdermal, subcutaneous, intramuscular, submuscular, or intragingival.
38. The method of claim 36, wherein the injection is in one or more tissues of the oral cavity.
39. The method of any one of claims 36-38, wherein the injection is for dermal filling, body contouring, facial contouring, and gingival filling.
40. The method of claim 39, wherein dermal filling is selected from filling wrinkles, filling fine lines, filling skin cracks, filling scars, and combinations thereof.

41. The method of claim 39, wherein gingival filling comprises filling gaps between the base of teeth.

42. The method of claim 39, wherein facial and body contouring is selected from creating pronouncements of structural features; correction of concave deformities; correction of age-related facial folds; and augmenting or repairing hard or soft tissue contour defects of the face and body due to aging, injury, and acquired or congenital deformities of the face or body.